Perrigo | PRGO - Sales Revenues

Stock Price
10.61
Daily Change
-0.23 -2.12%
Monthly
-6.19%
Yearly
-59.58%
Q2 Forecast
10.79

Perrigo reported $969M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Abbott USD 11.16B 300M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Dr.Reddys Laboratories INR 75.46B 11.81B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
J&J USD 24.1B 500M Mar/2026
Merck USD 16.29B 110M Mar/2026
Nestle CHF 45.26B 1.03B Dec/2025
Pacira USD 177M 19.87M Mar/2026
Perrigo USD 969M 141M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 281.62M 1.82M Mar/2026
Reckitt Benckiser GBP 7.26B 3.96B Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
Teva Pharmaceutical Industries USD 11.77B 2.86B Mar/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026
Zoetis USD 2.3B 100M Mar/2026